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ABSTRACT  
Current therapeutic approaches for Parkinson’s disease (PD) are based around treatments that 
alleviate symptoms but do not slow or prevent disease progression. As such, alternative strategies 
are needed. A promising approach is the use of molecules that reduce the function of LRRK2. Gain-
of-function mutations in LRRK2 account for a notable proportion of familial PD cases, and 
significantly, elevated LRRK2 kinase activity is reported in idiopathic PD. Here, we describe progress 
in finding therapeutically effective LRRK2 inhibitors, summarising studies that range from in vitro 
experiments through to clinical trials. LRRK2 is a complex protein with two enzymatic activities and a 
myriad of functions. This creates opportunities for a rich variety of strategies, but also increases the 
risk of unintended consequences. We comment on the strength and limitations of the different 
approaches and conclude that with two molecules under clinical trial and a diversity of alternative 
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Parkinson’s disease 
Parkinson’s disease (PD) is movement disorder that has been observed in humans since ancient 
times, but was first studied as a distinct condition by the English physician James Parkinson, who 
published his “essay on the shaking palsy” in 1817 (Parkinson, 1817). Today, PD is recognised as the 
second most common neurodegenerative disease, affecting up to 10 million individuals worldwide, 
with a lifetime risk estimated around 2% (Elbaz et al., 2002; Gan-Or et al., 2015). Despite so many 
years of study and so many affected individuals, PD is an incurable condition. 
PD is predominantly a disease of the elderly, with most sufferers over the age of 60 (Reeve et al., 
2014). The condition is usually considered both sporadic and idiopathic, with contributions to 
disease risk coming from an individual’s genetics and their lifetime exposure to environmental 
factors, but with age by far the most important factor (Farrer, 2006; Reeve et al., 2014). 
Nonetheless, clear patterns of Mendelian inheritance are apparent in around 10% of patients 
(Sveinbjörnsdottir et al., 2000; Rocca et al., 2004). Patients typically present with a tetrad of motor 
features, namely resting tremor, muscle rigidity, posture instability and bradykinesia (Postuma et al., 
2015). Of these, resting tremor is often the first symptom to present, and is perhaps the most 
distinctive of the condition when compared to other motor disorders. It is now well established that 
these oftentimes debilitating symptoms are due to the degeneration of dopaminergic neurons 
within the substantia nigra pars compacta, which leads to a depletion of the neurotransmitter 
dopamine (Postuma et al., 2015). PD is not limited to motor dysfunction however (Pfeiffer, 2016). 
Several neuronal networks are affected, causing patients to also suffer from psychiatric and 
dysautonomic problems, and as the disease progresses, cognitive problems can develop (Pfeiffer, 
2016). More common non-motor symptoms include anosmia, depression, and constipation. Since 
these non-motor symptoms can occur more than 10 years prior to the onset of motor symptoms and 
diagnosis, prodomal PD is currently a research area attracting great attention.  
From a pharmacological perspective, it is most important to emphasise that existing PD treatments 
only alleviate symptoms and do not delay or halt progression of the disease (AlDakheel et al., 2014). 
Current therapeutic approaches for PD are summarised in Table 1. The majority of these treatments 
aim to restore motor function by re-establishing dopamine signalling (AlDakheel et al., 2014), and 
are derived from pioneering studies by Arvid Carlsson who demonstrated that injection of the 
dopamine biosynthesis precursor L-dehydroxyphenylalanine (L-DOPA) rescued motor function in 
animal models (Carlsson et al., 1957). It took the best part of a decade to find a suitable dosing and 
delivery regimen for human PD patients (Cotzias et al., 1967), but oral L-DOPA, and conceptually 
similar dopamine receptor agonists, have been the mainstay of PD treatment ever since. For any 
drug, such enduring popularity would usually indicate that it is a highly efficacious and problem-free 
compound, and it is certainly true that after starting L-DOPA PD patients often experience a 
honeymoon period lasting several years, where motor symptoms may be in almost complete 
abeyance. But symptoms inevitably return as the disease progresses, and the dopamine 
replacement therapies themselves can cause some fairly serious side effects, not least L-DOPA-
induced dyskinesias (Tran et al., 2018). Furthermore, these treatments do not address the majority 
of non-motor symptoms, which typically do not involve loss of dopaminergic neurones (Chaudhuri et 
al., 2006; Postuma et al., 2015). PD patients will require additional medications to treat these 
symptoms, such as selective serotonin reuptake inhibitors for the treatment of depression 
(AlDakheel et al., 2014). But perhaps the most fundamental limitation of dopamine receptor 
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The need for new therapeutic strategies for PD is clear. Moreover, since the world’s population is 
ageing, it is also clear that this need is growing (Reeve et al., 2014). Over recent years, a great deal of 
research has therefore been directed towards the genetic causes of PD, in the hope that these will 
point the way to novel drug targets. Therapeutic strategies that target proteins involved in PD 
etiology offer great potential. In principle, such approaches may not only arrest PD progression, but 
may even be sufficient to prevent disease in the first place.  
The rest of this article deals with the current state of play regarding pharmacological inhibitors of 
leucine-rich repeat kinase 2 (LRRK2), the product of a gene that is strongly implicated as both a 
cause of familial PD and as an important risk factor contributing towards the more common sporadic 
form of the condition (Paisan-Ruiz et al., 2004; Zimprich et al., 2004; Nalls et al., 2014; Kluss et al., 
2019). For reasons we outline below, targeting LRRK2 may be fruitful not only for individuals with 
pathogenic LRRK2 mutations, but potentially also for the majority of PD patients whose LRRK2 status 
is likely to be normal. Nonetheless, LRRK2 inhibitors are far more likely to form part of a next 
generation of PD treatments, alongside other therapies targeting other genes involved in PD 
aetiology. For example, clinical trials are currently underway aiming to restore the function of the 
lysosomal enzyme β-glucocerebrocidase (GCase; the product of the GBA gene). Strategies employed 
include gene therapy (NCT04127578; clinicaltrials.gov) and compounds such as Ambroxol 
(NCT02941822, NCT04388969 and NCT02914366; clinicaltrials.gov) that are expected to act as 
molecular chaperones to improve the delivery of GCase to the lysosome (Maegawa et al., 2009; 
Migdalska‐Richards et al., 2017). Direct targeting of α-synuclein is also being pursued. For example, 
the aggregation inhibitor anle138b (Wagner et al., 2013) is in clinical trials (NCT04685265; 
clinicaltrials.gov), as is the c-Abl inhibitor nilotinib (NCT02281474; clinicaltrials.gov), which is 
expected to remove α-synuclein by promoting autophagy (Karuppagounder et al., 2014). It is hoped 
that these compounds – in particular when allied with methods to identify at-risk individuals, such as 
genetic screens and research into prodromal PD, to allow earlier intervention – will become the next 
generation of PD treatments that are so desperately needed. 
Leucine-rich repeat kinase 2 (LRRK2) 
Leucine-rich repeat kinase 2 protein (LRRK2) is the product of the LRRK2 gene. LRRK2 was originally 
discovered independently by two groups as the gene located within the so-called PARK8 locus – a 
region on chromosome 12 associated with autosomal dominant late-onset parkinsonism (Paisan-
Ruiz et al., 2004; Zimprich et al., 2004). Mutations in LRRK2 are now accepted as one of the most 
common causes of familial PD (Nalls et al., 2014; Kluss et al., 2019). Pathogenic LRRK2 mutations give 
rise to phenotypes that, at the individual level, are clinically indistinguishable from those of sporadic 
PD, including age of onset, symptoms, and patterns of neurodegeneration in nigrostriatal 
dopaminergic neurons. Post-mortem LRRK2 brains also display accumulation of Lewy Bodies – 
proteinaceous aggregates typically enriched in α-synuclein and ubiquitin – that are a pathological 
hallmark of PD (Kalia et al., 2015). Curiously, LRRK2 brains also frequently display Tau protein 
pathology; although the gene encoding Tau, MAPT, has been strongly implicated in sporadic PD via 
genome-wide association studies (GWAS), the accumulation of Tau is usually associated with other 
neurodegenerative conditions including Alzheimer’s disease (Iqbal et al., 2010; Nalls et al., 2014). 
Thus, LRRK2 may sit at the top of neurodegenerative cascades involving both α-synuclein and Tau. 
Complicating matters further, TDP-43 pathology, more usually associated with amyotrophic lateral 
sclerosis has been reported in a small number of LRRK2 brains (Wider et al., 2010; Ling et al., 2013), 
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Importantly, GWAS have also shown that LRRK2 has a major influence on an individual’s risk of 
developing sporadic PD (Satake et al., 2009; Simon-Sanchez et al., 2009; Do et al., 2011; Lill et al., 
2012). Thus, with gene variants of different severity either causing familial PD or contributing risk of 
sporadic PD, LRRK2 is considered a pleiomorphic risk locus for this condition (Cookson, 2015), and it 
is clear that the study of LRRK2 may have wider implications for other forms of neurodegenerative 
disease. 
Adding an extra layer of complexity, GWAS have also implicated LRRK2 as a factor in the genetic risk 
of Crohn’s disease (CD) (Barrett et al., 2008; Franke et al., 2010) and leprosy (Zhang et al., 2009; 
Wang et al., 2015), whilst other studies have linked LRRK2 to tuberculosis (TB) (Hartlova et al., 2018). 
LRRK2 has also been associated with the risk of cancer, but with conflicting results. Some studies find 
that the pathogenic LRRK2 variant G2019S increases the risk of cancer (Saunders-Pullman et al., 
2010; Inzelberg et al., 2012; Agalliu et al., 2015), but others do not (Allegra et al., 2014; Ruiz-
Martinez et al., 2014). Interestingly, loss of LRRK2 appears to increase risk of lung cancer (Lebovitz et 
al., 2021), an observation that may be germane to the long term use of LRRK2 inhibitors (see later in 
this article). In any case, the observations linking LRRK2 to CD, TB and leprosy are curious, since 
these conditions share some clear similarities with each other (e.g. they are all chronic inflammatory 
conditions with other genetic loci in common), but similarities with PD are less obvious. Whether 
LRRK2 dysfunction has a common role in all four conditions or whether the molecular mechanism in 
PD is distinct remains to be seen, but it is interesting to note that although that no shared 
pathogenic variants have been identified, the protective R1398H variant appears to be common to 
risk of CD and PD (Tan et al., 2010; Ross et al., 2011; Hui et al., 2018). As such, it is easy to imagine 
that, at the very least, research into LRRK2 in PD could also have important implications for these 
non-neurodegenerative conditions. 
LRRK2 itself is a large (2527 amino acid) and very unusual protein that belongs to the ROCO family of 
GTPases and contains multiple functional domains (Paisan-Ruiz et al., 2004; Zimprich et al., 2004; 
Gotthardt et al., 2008). The structure of LRRK2 is depicted in Figure 1. In addition to the four protein-
protein interaction domains, LRRK2 contains domains conferring both serine-threonine kinase 
activity and GTPase activity, the latter via the combination of a Ras of complex proteins (Roc) 
domain and a c-terminal of Roc (COR) domain, which are often collectively referred to as a RocCOR 
tandem domain (Gotthardt et al., 2008). A number of pathogenic mutations have been found, all of 
which encode single amino acid substitutions with the Roc, COR and kinases domains, although a 
relatively common variant associated with increased risk encodes a G2385R amino acid substitution 
with the WD40 domain, at the C-terminus of the protein (Berwick et al., 2019; Kluss et al., 2019). 
Typically, LRRK2 exists in cells as both homodimers and monomers, with dimerization suggested to 
regulate LRRK2 subcellular location and function (Ho et al., 2018). Fascinatingly, monomers are 
generally cytosolic, whilst dimers are predominantly located on organelle membranes (Nichols et al., 
2010; Berwick and Harvey, 2012), and membrane-bound LRRK2 has been reported to possess a 
higher kinase activity (Berger et al., 2010). Thus, LRRK2 dimerization and membrane recruitment has 
been suggested to play a role in kinase activation, perhaps in a mechanism governed by the 
membrane-bound small GTPase Rab29, which has been shown to bind LRRK2 and increase its kinase 
activity in cells (Liu et al., 2018; Purlyte et al., 2019). 
The biological function of LRRK2 within cells remains unclear, largely because this protein has been 
linked to a multitude of different cell biological processes and a clear front runner has yet to emerge 
from the pack. For example, LRRK2 has been linked to effects on cell signalling, microtubule and 
other cytoskeletal dynamics, ciliogenesis, autophagy, endocytosis, synaptic vesicle trafficking, and 
the biology of numerous cellular organelles such as mitochondria, the trans-Golgi network and 
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lysosomes (reviewed by Berwick et al., 2019). Complicating things further, there is no real 
agreement over the type of cells in which LRRK2 dysfunction is most important for PD, with 
published data supporting many neural cell types and also immune cells (Berwick et al., 2019). In 
principle therefore, LRRK2 dysfunction could either cause degeneration of dopaminergic neurons via 
a cell autonomous process or via a non-cell autonomous neuroinflammatory mechanism – or 
potentially via both. 
Nonetheless, within the context of this review, the uncertainty regarding LRRK2 function is not of 
great importance. This is because when it comes to the effects of LRRK2 pathogenic mutations on 
LRRK2 itself, there is clear consensus on two key points:  
1. All pathogenic LRRK2 mutations increase both LRRK2 autophosphorylation and the LRRK2-
mediated phosphorylation of certain Rab small GTPases in cells. Whether all these mutations 
technically increase LRRK2 kinase activity is debatable, since only the common G2019S kinase 
domain mutation reproducibly increases kinase activity in biochemical assays performed in 
vitro (Greggio and Cookson, 2009). Furthermore, the G2385R risk variant is actually reported 
to reduce kinase activity in these experiments (Rudenko et al., 2012). However, this argument 
is ultimately a semantic one – the effect of all PD-causing or PD risk mutations in LRRK2 is to 
increase substrate phosphorylation in vivo (Berwick et al., 2019; Kluss et al., 2019). To most 
intents and purposes, therefore, they can be considered to increase kinase activity; at the very 
least, there are gains of kinase function. 
 
2. All pathogenic LRRK2 mutations within the Roc or COR domains increase the fraction of GTP-
bound LRRK2 relative to GDP-bound LRRK2. This phenomenon is achieved either via increased 
binding of the LRRK2 Roc domain to GTP, or via a decrease in the catalytic activity of this 
domain (i.e. there is less hydrolysis of GTP to GDP), or via a combination of both mechanisms 
(Nixon-Abell et al., 2016b). Supporting the idea that GTP-bound LRRK2 is a more pathogenic 
species, the protective LRRK2 risk variant, R1398H, displays decreased GTP-binding and 
increased GTPase activity, and can therefore be expected to exist in a more GDP-bound state 
(Nixon-Abell et al., 2016a). 
Thus, there are clear and largely unambiguous correlations between increased LRRK2 kinase 
function in vivo and PD, and between the increased association of LRRK2 with GTP and PD. How 
these mechanisms relate to each other is not yet fully understood, with biochemical evidence 
indicating that the two enzymatic activities of LRRK2 are to some extent interdependent. However, 
the fact that all pathogenic mutations promote substrate phosphorylation under physiological 
conditions indicates that increased kinase function is the pathogenic “output” of LRRK2, even if the 
increased kinase function isn’t always increased kinase activity per se. Underscoring this idea, 
increased LRRK2 autophosphorylation and increased phosphorylation of the LRRK2 substrate Rab10 
has also been observed in PD and animal models of PD that do not involve pathogenic LRRK2 
mutations (Di Maio et al., 2018). Importantly, these include post-mortem brains from human 
patients with sporadic PD, as well as brains from rats that over-express α-synuclein or have been 
treated with the environmental toxin rotenone (Di Maio et al., 2018). As such, it can be assumed 
that multiple causes of PD – genetic and environmental – can give rise to increased LRRK2 kinase 
function and thus PD. 
Although it has taken some time for the experimental evidence to convincingly support this idea, 
largely due the time taken for researchers to identify Rab proteins as the first widely agreed bona 
fide LRRK2 substrates, autosomal dominant mutations in a kinase gene can logically be expected to 
increase the enzymatic activity of that kinase. Thus, from the perspective of the pharmaceutical 
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industry, the identification of LRRK2 as an autosomal dominant cause of hereditary PD was sufficient 
rationale to begin developing compounds that reduce LRRK2 kinase activity, irrespective of how well 
the assumed increased kinase function had actually been demonstrated empirically. As a result, the 
quest to develop LRRK2 inhibitors as candidate therapeutic treatments for PD began very early, with 
multiple companies involved, as well as considerable backing from the charitable sector. In fact, the 
pursuit of a clinically usable LRRK2 inhibitor has progressed to such an extent that clinical trials of 
one such compound in sporadic PD patients were announced only a matter of weeks after the first 
evidence that LRRK2 kinase function is actually increased in this cohort (Denali Therapeutics, 2018; 
Di Maio et al., 2018). In short, the progress of LRRK2 drug development relative to basic research 
into this protein is quite remarkable. 
In the subsequent three sections of this article we summarise the development of conventional 
LRRK2 kinase inhibitors, while also identifying potential risks and challenges in the road ahead. For 
more detailed descriptions of the chemistry of these molecules we point the reader to the following 
more specialised reviews (Hatcher et al., 2017; Domingos et al., 2019). Later in the manuscript we 
branch out to alternative pharmacological strategies to reduce the function of this protein, which 
together create a rich palette of potential therapeutic options.  
 
ATP-competitive LRRK2 kinase inhibitors  
The majority of molecules targeting LRRK2 have been conventional or “Type I” kinase inhibitors, 
which compete with ATP for binding to the ATP-binding pocket withing the kinase domain (Hatcher 
et al., 2017; Lu et al., 2020). This story inevitably began with compounds that were a long way from 
candidate drugs ready to enter clinical trials, but over the years these molecules have evolved to 
have superior pharmacological profiles and one compound is now in clinical trials.  
The first compounds reported to inhibit LRRK2 kinase activity were either broad range kinase 
inhibitors able to inhibit LRRK2 with high potency, but very low selectivity, e.g. staurosporine, which 
has IC50 values for LRRK2 of 1-2 nM (Anand et al., 2009; Covy and Giasson, 2009), or a series of Rho 
kinase inhibitors that were found to inhibit LRRK2 and Rho kinases with similar high nanomolar 
potencies (Nichols et al., 2009). Fortunately, these compounds were swiftly superseded by two more 
selective molecules, LRRK2-IN-1 (Deng et al., 2011) and CZC-25146 (Ramsden et al., 2011), that  were 
identified specifically as LRRK2 inhibitors via kinase inhibitor library screens. Both these compounds 
are reported to inhibit LRRK2 with IC50s in the low nanomolar range, and exhibit decent selectivity; 
for example, LRRK2-IN-1 was found to display greater than 90% inhibition towards only 12 out of 440 
kinases using an Ambit KINOMEscan that measures the binding of drugs to a panel of kinases as a 
proxy for kinase inhibition (Karaman et al., 2008; Deng et al., 2011).  
The chemical structures of LRRK2-IN-1 and CZC-25146 and other selective LRRK2 inhibitors that are 
specifically mentioned within this article are shown in Figure 2. 
In addition to LRRK2-IN-1 and CZC-25146, the first generation of LRRK2 inhibitors also included 
another  high molecular weight diaminopyrimidine  named TAE684, a repurposed ALK inhibitor with 
a similar potency but a slightly inferior selectivity (Zhang et al., 2012). Aminopyrimidines were not 
the only structural category represented however, with GSK2578215A, a potent (IC50 = 9 nM) and 
selective (90% inhibition towards only 3 out of 449 kinases) arylbenzamide,  also being reported in 
2012 (Reith et al., 2012). These four compounds have been integral to a great deal of basic research 
carried out over subsequent years, aided in part by the Michael J. Fox Foundation making them 
easily available to scientists worldwide. Nonetheless, as drugs for the clinic, all four compounds 
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perished early in the pipeline. LRRK2-IN-1 and CZC-25146 had the critical failing of being unable to 
cross the blood-brain barrier, which is clearly a fundamental requirement of any pharmaceutical 
aimed at treating neurodegenerative disease. Somewhat surprisingly, the structurally similar but 
larger compound TAE684 did enter brain in rodents, but it was found to be ineffective as a LRRK2 
inhibitor in this organ. GSK2578215A, which is appreciably smaller than all three aminopyrimidine 
molecules, also crossed the rodent blood brain barrier with little effect on Lrrk2. 
Given that LRRK2-IN-1, CZC-25146 and TAE684 are all similar in structure, it is unsurprising that a 
great many of the next generation of LRRK2 kinase inhibitors were smaller aminopyrimidine 
molecules that were developed with the hope of retaining potency and selectivity for LRRK2, while 
facilitating access to the brain. A number of such compounds were published in the next few years 
including HG-10-102-01 (Chen et al., 2012; Choi et al., 2012) and a series of compounds – G1023, 
GNE-7915, GNE-0877, and GNE-9605 –  made by Genentech (Estrada et al., 2012, 2014). All these 
compounds have potencies in the low (or sub) nanomolar range, excellent selectivity, and are able to 
enter the brains of mice and inhibit Lrrk2 in vivo. The Genentech compounds were also tested in rats 
and cynomolgus monkeys, where they were found to have good pharmacokinetic and drug 
metabolism profiles (Estrada et al., 2012, 2014). Thus, LRRK2 kinase inhibitors moved from purely in 
vitro tools to compounds that could be used to study LRRK2 in the brains of animal models. 
Over the next few years, a number of other structurally distinct LRRK2 kinase inhibitors (i.e. neither 
aminopyridines nor arylbenzamides) have been reported in the scientific literature, as these 
compounds continue to evolve and improve. Structural categories include pyrrolopyrimidines such 
as Pfizer’s PF-06447475 (Henderson et al., 2015), indazoles such as Merck’s MLi-2 (Fell et al., 2015), 
and thiophenes, also from Merck (Greshock et al., 2016). In addition, further types of organic 
molecules that have not been described in the scientific literature are the subject of patents for use 
as LRRK2 inhibitors, such as macrocyclic derivatives from GlaxoSmithKline and Ipsen Pharma (Ding 
and Ren, 2020). For a detailed review of the chemistry, we refer the reader to existing work in this 
area (Hatcher et al., 2017; Domingos et al., 2019).  
One recent development that is worthy of mention, however, is the discovery of ATP-competitive 
LRRK2 inhibitors that exhibit selectivity for the pathogenic G2019S LRRK2 variant over wild-type 
LRRK2 (Garofalo et al., 2020). Via compound library screening followed by in silico docking analysis 
and systematic chemical modifications, Garofalo and colleagues identified a number of indazole 
molecules displaying selectivity for G2019S (Garofalo et al., 2020). The most selective compound was 
reported to have a >300x greater potency in cellular assays and >200x greater potency in vitro. As 
the authors themselves rightly observe, this “is remarkable, given that G2019S-LRRK2 differs from 
WT-LRRK2 only by a single amino acid” (Garofalo et al., 2020). Unfortunately, this molecule is 
unlikely to be developed further as it is unable to cross the blood-brain barrier, but we note that 
another G2019S-selective indazole compound identified in the same work has since been shown to 
inhibit LRRK2 kinase activity in peripheral blood mononuclear cells (PBMCs) from homozygous 
G2019S LRRK2 patients, but not in cells from wild-type controls (Bright et al., 2021). Thus, even 
though these molecules may only be suitable for G2019S LRRK2 PD patients, there is clearly a lot of 
potential in this project and we await further developments. 
Taking this section as a whole, it is evident that there are a multitude of promising ATP-competitive 
LRRK2 kinase inhibitors in the pipeline. As therapeutics for the treatment of PD, most of these 
compounds will inevitably fall by the wayside, but with a diversity of chemical structures available, 
there are good grounds for optimism. A variety of chemical structures means a greater range of 
pharmacological properties and a better chance of finding a drug that is potent, selective, and free 
from adverse effects.  Later in this article we will focus on LRRK2 inhibitors that are, or have been, 
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used in human clinical trials, but before we get to that point, we will first comment on certain areas 
of concern that have been raised in pre-clinical studies.  
 
Areas of concern for the LRRK2 kinase inhibitor drug pipeline 
As mentioned, LRRK2 kinase inhibitors have been in development for well over a decade as a 
potential therapeutic strategy for PD. Nonetheless, there have long been concerns about this 
strategy that go beyond the now resolved difficulty in demonstrating elevated LRRK2 kinase function 
for any variant other than G2019S. For example, LRRK2 kinase inhibitors have been shown to display 
similar effects to pathogenic mutants in some cellular assays, for example their effects on canonical 
Wnt signalling (Berwick and Harvey, 2012; Berwick et al., 2017) and binding of LRRK2 to filamentous 
microtubule structures (Blanca Ramirez et al., 2017; Schmidt et al., 2019). Thus, there is a potential 
that LRRK2 inhibition may increase certain PD symptoms. In addition, there is evidence that 
prolonged inhibition can lead to loss of protein stability, thereby compromising all functions of 
LRRK2, not just those that are kinase-dependent (West, 2017). Whilst this can in principle be 
addressed by keeping the therapeutic dose within a tight window, this is potentially a serious 
problem, as LRRK2 has hundreds of reported interacting partners and is believed also to act as a 
scaffolding protein, not just as a kinase (Lewis and Manzoni, 2012; Berwick et al., 2019).  
The greatest worry perhaps inevitably comes from in vivo studies of Lrrk2 knockout mice and rats. 
Mice that are double knockout for both Lrrk2 and its paralog Lrrk1 display neurodegeneration 
(Giaime et al., 2017), but since animals that only lack Lrrk2 have no overt neurological phenotypes 
(reviewed by Seegobin et al., 2020), these concerns do not relate to the brain. Instead, Lrrk2 
knockout mice and rats display an unusual vacuolated phenotype in their kidneys, liver and lung 
(Tong et al., 2010; Baptista et al., 2013; Ness et al., 2013; Seegobin et al., 2020). None of these 
alterations appear to have any significant impacts on the health of these laboratory animals, but the 
lung phenotype is a particular concern given that respiratory problems are very common in PD (van 
de Wetering-van Dongen et al., 2020), so any further compromise to lung function could ultimately 
lead to a worsened clinical outcome. This concern was intensified following an investigation into the 
effect of two of the Genentech aminopyridine inhibitors, GNE-7915 and GNE-0877, in cynomolgus 
monkeys (Fuji et al., 2015). Worryingly, treatment of these animals with either compound caused 
vacuolated type II pneumocytes, which was very consistent in appearance with the lung phenotype 
of Lrrk2 knockout mice and rats. Subsequently, a similar effect was observed in mice treated with 
the indazole LRRK2 inhibitor MLi-2 developed by Merck (Fell et al., 2015). However, a recent 
dedicated toxicological study using GNE-7915, MLi-2 and the Pfizer LRRK2 inhibitor PFE-360 in 
cynomolgus has indicated that these fears may be exaggerated (Baptista et al., 2020). Although each 
compound induced the same vacuolated type II pneumocyte phenotype, thereby confirming that 
this is an on-target effect of LRRK2 kinase inhibition, lung function studies on the GNE-7915 and MLi-
2-treated animals did not reveal any apparent limitations (the PFE-360-treated cohort were not 
examined). Importantly, other experiments indicate that the phenotype is reversible following 
withdrawal from treatment, and that the PFE-360 compound in particular might be able to operate 
at a no-effect dose, where brain LRRK2 kinase activity is inhibited, but the lung phenotype is not 
observed (Baptista et al., 2020). As such, the worst case scenario seems to be that the lung 
phenotype can be avoided with adequate dosing and, if it does occur, the phenotype can be treated 
and is unlikely to have much of an impact anyway. Supporting this further are recent studies of 
humans carrying heterozygous loss-of-function LRRK2 variants. It had already been reported that 
individuals with low expression of LRRK2 have no increased risk of PD (Blauwendraat et al., 2018), 
but the work of Whiffin and colleagues has extended this to a wide range of clinical outcomes 
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(Whiffin et al., 2020). Using health records of  individuals heterozygous for LRRK2 variants containing 
premature stop codons, this group reported no increased frequency of “lung, liver, kidney, 
cardiovascular system, nervous system, immunity or cancer” phenotypes (Whiffin et al., 2020). 
However, these results are to some extent contradicted by a more recent report associating LRRK2 
loss-of-function with a type of lung cancer appears to be type II pneumocyte in origin (Lebovitz et al., 
2021). This group had previously reported lowered LRRK2 expression in lung adenocarcinoma 
(Lebovitz et al., 2015), but have since looked at the connection in greater detail. They report that 
lower levels of LRRK2 are associated with decreased patient survival, and that Lrrk2 KO mice are 
more prone to developing lung adenomas when exposed to urethane, a cigarette smoke carcinogen 
(Lebovitz et al., 2021). These results are concerning, but it is probably pertinent to observe that 
lower LRRK2 expression is most strongly correlated with lung cancer in patients who are smokers, 
and that there is currently little evidence to suggest decreased LRRK2 expression is sufficient to 
cause lung cancer (Lebovitz et al., 2021). Thus, LRRK2 inhibitors may not be suitable for current or 
recent smokers, but otherwise the risk of lung cancer appears small.     
A further complication is how to reliably measure the extent of LRRK2 kinase inhibition within the 
brains of patients, such that clinicians can establish an optimal dose and monitor treatment 
progression in their patients. Existing biomarkers, such as Rab protein phosphorylation (Steger et al., 
2016; Eyers, 2018) or LRRK2 autophosphorylation on serine-1292 (Sheng et al., 2012), which can be 
measured with phospho-specific antibodies, appear to be faithful proxies for LRRK2 kinase function 
in brain tissue from experimental animals, but these assays cannot easily be replicated on humans. 
Less invasive procedures will be needed, for example proteins or metabolites present in patient 
blood or urine samples, although correlating these readouts with LRRK2 kinase inhibition in brain 
tissue is going to be a tough ask. With this in mind, we note that certain 
bis(monoacylglycerol)phosphates (BMPs), phospholipids that are considered specific to lysosomes, 
have been reported to be increased in the urine of LRRK2 PD patients (Alcalay et al., 2020), and also 
decreased in the urine of both cynomolgus monkeys treated with LRRK2 kinase inhibitors and Lrrk2 
knockout mice (Fuji et al., 2015). As such, urine BMP levels may be an ideal non-invasive biomarker. 
It should be noted that sporadic PD patients do not appear to have elevated urine BMP levels 
compared to healthy controls (Alcalay et al., 2020), however the same study found that in PD 
patients, urine BMP levels appear to be inversely correlated with cognitive performance irrespective 
of LRRK2 status. Thus the overall difference in urine BMP levels between sporadic PD and control 
cohorts is likely a consequence of heterogeneity within each group, and that at an individual level at 
least, urine BMP levels may be a faithful biomarker of disease progression (Alcalay et al., 2020). The 
full potential of this biomarker remains to be established, but unsurprisingly, this biomarker is 
already being used in clinical trials of LRRK2 inhibitors (Denali Therapeutics, 2020).  
LRRK2 kinase inhibitors in clinical trials 
Although the field is very crowded, to date just two LRRK2 kinase inhibitors have been used in 
clinical trials: compounds DNL-201 and DNL-151, which are manufactured by Denali Therapeutics. 
Neither of these compounds have been described in the scientific literature, although it has been 
observed that this company published four patents that cover the use of an array of 
aminopyrimidine compounds in 2017 and 2018 (Ding and Ren, 2020), around the time trials began. 
In phase 1a trials, both compounds were well tolerated in healthy volunteers at doses that “achieved 
high levels of cerebrospinal fluid (CSF) exposure, robust target engagement as measured by two 
blood-based biomarkers of LRRK2 activity, and effects on biomarkers of lysosomal function” (Denali 
Therapeutics, 2018). It can be assumed that the blood biomarkers of LRRK2 activity were 
measurements of LRRK2 autophosphorylation or Rab protein phosphorylation, or alternatively, 
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phosphorylation of LRRK2 at one or more of a series of serine residues within the LRR domain that 
are dependent on, but not directly mediated by, LRRK2 kinase activity (Kelly and West, 2020). 
Indeed, phosphorylation of Rab10 in PBMCs and LRRK2 phosphorylation on the serine-935 LRR 
domain site in PBMCs and whole blood are mentioned as secondary outcome measures within the 
phase 1b clinical trial listings for the DNL-201 and DNL-151 (NCT03710707 and NCT04056689 
respectively; clinicaltrials.gov). The assay of lysosomal function is not described in the clinical trial 
listings, but is likely to be urine BMP levels, as mentioned in a subsequent announcement (Denali 
Therapeutics, 2020).  
The trial has been expanded to PD patients in phase 1b trials, with both compounds reporting good 
results. In light of the lung phenotype and the particular risk of respiratory impairment in PD, this is 
good news. Nonetheless, Denali have announced their intention to focus only on DNL-151 as phase 
1b trials are extended to cover a wider range of doses, as this compound has “pharmacokinetic 
properties that provide additional dosing regimen flexibility” (Denali Therapeutics, 2020).  
So what is the situation with other LRRK2 kinase inhibitors? At present, with Denali over two years 
into testing, it can be assumed that other companies are waiting for the full results of DNL-151’s 
phase 1 and 2 trials, before deciding whether to press ahead with their own compounds. Watching 
keenly will be Cerevel, who have a LRRK2 inhibitor listed as one of their pipeline drugs on their 
website (Cerevel, 2021) and have acquired the rights to Pfizer’s neurological disease compounds. 
Presumably this includes the pyrrolopyrimidine compound PFE-360, which, as mentioned above, was 
found to have a no-effect dose at which it inhibited LRRK2 in monkey brains but did not induce any 
lung phenotype (Baptista et al., 2020). Also paying close attention will be Merck, whose MLi-2 
compound also showed signs of a no-effect dose, albeit within a much narrower window than was 
observed for PFE-360 (Baptista et al., 2020). Perhaps importantly, this drug has an especially high 
potency, with an IC50 in the high picomolar range (Fell et al., 2015). Clearly, Cerevel and Merck will 
not be the only interested parties; thus, while the world plays wait and see, we can at least do so 
safe in the knowledge that if DNL-151 fails there are plenty of alternative options. 
 
Other therapeutic approaches to reduce LRRK2 function 
Whilst there are plenty of alternative LRRK2 kinase inhibitors to DNL-151, there are also plenty of 
therapeutic strategies for reducing the function of LRRK2 that do not involve classical ATP-
competitive kinase inhibition (Figure 3). This smorgasbord of approaches broadens the targets of 
potential therapeutic drugs far beyond the kinase domain, and includes molecules that affect LRRK2 
conformation, protein-protein interactions, GTPase activity and even LRRK2 mRNA. We describe 
these molecules in the following sections. 
 
LRRK2 GTP-binding inhibitors  
In addition to the LRRK2 kinase domain, the second enzymatic activity of LRRK2 represents another 
interesting drug target. Since there are only four ROCO GTPases in humans – LRRK1, LRRK2, DAPK1 
and MASL1 (Tomkins et al., 2018) – molecules targeting LRRK2-GTP binding have the potential to be 
especially selective. Moreover, there is also sound rationale for such compounds, as decreasing the 
proportion of pathogenic LRRK2 existing in a GTP-bound state can be expected to reduce LRRK2 
kinase activity and would likely be neuroprotective. Therefore, selective and blood-brain barrier-
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permeable molecules that block LRRK2-GTP binding represent an alternative option to explore 
beyond kinase inhibition.  
Surprisingly though, research on LRRK2 GTPase inhibitors has not been prolific and very few research 
groups in industry or academia have actively taken this route. To date, only Wanli Smith’s group has 
reported LRRK2 GTP-binding inhibitors, the first of which, compounds 68 and 70, were identified via 
a computer-aided drug discovery screen (Li et al., 2014). In addition to blocking LRRK2-GTP binding 
in cells, these compounds were also able to reduce LRRK2 autophosphorylation, thereby confirming 
the secondary effect of inhibiting LRRK2 kinase activity (Li et al., 2014). Demonstrating their 
potential, both compounds promoted the survival of cultured neurons, while compound 68 also 
reduced lipopolysaccharide-induced neuroinflammation in a mouse model (Li et al., 2014). In 
subsequent work, this group reported an optimised analogue of compound 68, FX2149, which is 
more brain-penetrant and correspondingly more potent in the same mouse model (Li et al., 2015). 
To the best of our knowledge only one other group have published with these compounds. 
Fascinatingly, Blanca Ramirez and colleagues reported that compounds 68 and 70 reverse the 
increased binding of the pathogenic R1441C LRRK2 variant to filamentous microtubule structures 
(Blanca Ramirez et al., 2017). This is in contrast to LRRK2 kinase inhibitors, which, as mentioned 
above, were found to behave like PD-causing mutations in these assays (Blanca Ramirez et al., 2017). 
Although these compounds are under patent, we are unaware of any moves toward entering LRRK2-




Whilst DNL-151 is the only chemical inhibitor of LRRK2 currently in clinical trials, it is not the only 
molecule seeking to reduce LRRK2 function being examined in humans. As part of a collaboration 
between Biogen and Ionis Pharmaceuticals, intrathecal injection of a molecule called BIIB094 is 
currently being studied in a phase 1 clinical trial (NCT03976349; clinicaltrials.gov). As Biogen state on 
their website, BIIB094 is an antisense oligonucleotide (Biogen, 2021). Antisense oligonucleotides 
(ASOs) are single-stranded DNA molecules of varying lengths that are designed to bind specifically to 
an mRNA molecule of interest via base-pair complementarity, typically causing protein synthesis 
from that mRNA to be blocked (Chery, 2016). The nucleotides within ASOs are typically chemically 
modified to prevent degradation by nucleases, while also facilitating uptake across the plasma 
membrane and enhancing binding to RNA (Silva et al., 2020). Importantly, since the mode of delivery 
used by Biogen and Ionis is intrathecal injection, i.e. directly into the CSF, this strategy obviates the 
need for BIIB094 to cross the blood-brain barrier. The use of ASOs to target LRRK2 still carries many 
of the same concerns as use of LRRK2 kinase inhibitors, and intrathecal delivery is a fairly invasive 
means of drug delivery, so there are evidently downsides to this approach. Nonetheless, it is 
important to note that the blood-brain barrier works in both directions, so intrathecal delivery will 
greatly reduce the chance of adverse effects in the periphery, not least the now familiar lung 
phenotype. 
Fascinatingly, ASOs are already being used in the clinic for the treatment of spinal muscular atrophy, 
a rare neurodegenerative disease of motor neurons (Kolb and Kissel, 2015). In this case, the ASO, 
which is referred to as nusinersen, is not acting to repress its target mRNA, but to prevent the 
binding of a splicing factor, thereby promoting alternative splicing (Chiriboga et al., 2016). More 
conventional ASOs that repress gene expression have not yet progressed so far through the drug 
development pipeline for use in neurodegenerative diseases, but show promise. Most notably, these 
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molecules have been shown to decrease mutant gene expression and correspondingly improve the 
clinical symptoms in pre-clinical models with a range of different polyglutamine repeat disorders. 
These include Huntington’s disease, spinal and bulbar muscular atrophy and a number of types of 
spinocerebellar ataxia (Silva et al., 2020). Treatments have only reached the clinical trial stage for 
Huntington’s disease, but results have been impressive. In particular, ISIS3139 (also known as 
RO7234292), an ASO also produced by Ionic Pharmaceuticals but this time working with Hoffman-La 
Roche, was found to produce no serious adverse effects while also lowering expression of mutant 
Huntingtin in the CSF in a combined phase 1 and 2 clinical trial (NCT02519036; clinicaltrials.gov) 
(Tabrizi et al., 2019). ISIS3139 has since progressed to a phase 3 trial (NCT03761849; 
clinicaltrials.gov), with results expected in late 2022. 
It is also worth observing that other ASOs are under investigation for use in Huntington’s disease, 
which, unlike ISIS3139, specifically target mRNA produced by the disease-causing allele and not the 
wildtype (Silva et al., 2020). This is potentially significant, since this strategy should in principle avoid 
reducing all huntingtin expression, thereby protecting the essential functions of this protein. 
Theoretically, PD patients with LRRK2 mutations (although not sporadic PD patients) could be 
treated in a similar way. However, the ability to select between mutant and wildtype that differ only 
by a single base-change is going to be considerably more challenging than mutations like the 
expanded CAG-repeats causing Huntington’s disease. 
Allosteric inhibitors of LRRK2 kinase activity 
Allosteric kinase inhibitors can be defined as compounds that inhibit the enzymatic activity of a 
kinase by binding the kinase outside its ATP-binding site, and thus reducing kinase activity in an ATP 
non-competitive manner (Lu et al., 2020). In principle, the GTPase inhibitors described above, which 
bind the LRRK2 Roc domain and indirectly reduce LRRK2 kinase activity, meet this definition, but we 
have chosen to classify them separately, since kinase inhibition is not their primary objective. In 
practice, allosteric inhibitors are more likely to bind the kinase domain. There are advantages and 
disadvantages with any therapeutic strategy, but allosteric compounds have the potential to 
increase selectivity, by targeting regions that are less conserved than the ATP-binding pocket, 
although designing such molecules is more challenging.  
Recently, Schaffner and colleagues used a high-throughput screen of FDA-approved compounds to 
identify a physiological form of vitamin B12 (50-deoxyadenosylcobalamin, or AdoCbl) as a non-ATP 
competitive, “mixed-type” allosteric inhibitor of LRRK2 kinase activity (Schaffner et al., 2019). Since 
vitamin B12 levels are inversely correlated with PD progression (Christine et al., 2018), these 
observations suggest an intriguing, if speculative, hypothesis that endogenous vitamin B12 levels 
may be affecting PD progression via modulation of LRRK2, and that AdoCbl may be a bona fide 
endogenous inhibitor of LRRK2 activity. In any case, with a reported IC50 of ~1 μM in vitro, AdoCbl is 
considerably less potent than conventional LRRK2 inhibitors, although the authors suggest that 
AdoCbl is likely to be highly selective for LRRK2 as this molecule is structurally dissimilar to any other 
known kinase inhibitor. This last point clearly needs to be tested empirically. In any case, this 
molecule was able inhibit LRRK2 kinase activity and neurotoxicity in both in vitro and in vivo models 
carrying pathogenic LRRK2 variants (Schaffner et al., 2019). The exact location(s) within LRRK2 to 
which AdoCbl binds was not identified but based on enzymological data can be assumed to be 
distinct site(s) within the LRRK2 kinase domain, but outside the ATP-binding pocket. The authors also 
report that AdoCbl disrupts LRRK2 dimerization and promotes the proteolytic degradation of this 
protein. How these observations fit together mechanistically is not yet known, but since LRRK2 
dimers have greater kinase activity than LRRK2 monomers, it is tempting to speculate that AdoCbl 
may be inhibiting LRRK2 kinase by preferentially binding to dimeric LRRK2 and inducing 
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monomerization. This story is clearly at its infancy and therapeutic potential of AdoCbl is unclear, 
but its identification as a new allosteric inhibitor of LRRK2 may at least open the door to the 
discovery of other similar molecules. 
One strategy for the development of allosteric kinase inhibitors of LRRK2 that may be slightly less 
useful is the development of “Type II” kinase inhibitors that target the DFGψ motif (sometimes 
abbreviated to DFG) of the kinase domain activation loop (Schmidt et al., 2019; Lu et al., 2020). 
(Type II allosteric inhibitors in general bind to kinase domain activation loops; DFGψ is a conserved 
sequence of amino acids with the activation loop, where D, F and G are aspartic acid, phenylalanine 
and glycine, and ψ represents a hydrophobic residue.) Importantly, type II kinase inhibitors are only 
able to bind kinase domain activation loops that are in an inactive “DFG-out” conformation. In doing 
so, these compounds prevent the conformational change to an active “DFG-in” conformation that is 
required to allow access of ATP to the adjacent ATP-binding pocket (Schmidt et al., 2019). As such, 
Type II kinase inhibitors block kinase activity by gating access to ATP, rather than by competing with 
ATP. The limitation of developing Type II kinase inhibitors that target the DFGψ motif for LRRK2 is 
that this is the location of the amino acid substitutions encoded by two pathogenic mutations, 
G2019S and I2020T. Significantly, both G2019S and I2020T stabilise the LRRK2 activation loop in the 
active DFG-in conformation (Liu et al., 2013; Ray et al., 2014). Given this, Type II kinase inhibitors 
that target the DFGψ motif of LRRK2 can be expected to be less effective against these pathogenic 
variants than against wildtype LRRK2.  
This expectation is supported by experimental data. To date, several Type II inhibitors have been 
reported, including four compounds identified by Liu and colleagues using molecular docking of 
previously described Type II allosteric inhibitors of other kinases to a structural model of the LRRK2 
kinase domain (Ray and Liu, 2012; Liu et al., 2013). Two of these inhibitors target the activation loop 
hinge region, rather than the DFGψ motif, and these compounds displayed little difference in 
potency when tested against wildtype LRRK2 and the G2019S and I2020T variants (Ray and Liu, 
2012). By contrast, the two DFGψ motif inhibitors showed clear preferences for wildtype LRRK2, 
including the most potent compound, ponatinib (O’Hare et al., 2009), which has an in vitro IC50 for 
wildtype LRRK2 of 31 nM, but only 200 nM and 600 nM for G2019S and I2020T respectively (Ray and 
Liu, 2012). Taken together, these observations suggest that Type II kinase inhibitors that target the 
DFGψ motif will not be suitable for patients with G2019S or I2020T LRRK2 mutations, although there 
is no a priori reason why they may not be a valid therapeutic strategy for patients with mutations 
outside the LRRK2 kinase domain, or for idiopathic PD. There is also no reason to doubt the potential 
of Type II kinase inhibitors that target other parts of the activation loop. In addition to the hinge 
region, Ray and Liu observed that a series of cysteine residues located near the ATP binding site 
might be a fruitful site for developing covalent LRRK2 inhibitors (Ray and Liu, 2012).  
Evidence of neuroprotection provided by LRRK2 inhibitors or LRRK2 ASOs in PD-related animal 
models Pre-clinical data – in particular, more physiologically relevant studies performed in animal 
models – may provide some pointers towards the results we might reasonably expect in patients. In 
this section, therefore, we briefly summarise experiments assessing the ability of LRRK2 kinase 
inhibitors and ASOs to promote cell survival in PD-relevant animal models.  
Since LRRK2 transgenic animals do not have a robust neurological phenotype (Daniel and Moore, 
2015; Seegobin et al., 2020), in vivo investigations into neuroprotection offered by LRRK2 kinase 
inhibitors have tended to use viral expression systems to transduce animal brains with high levels of 
a pathogenic protein. In studies using over-expression of the pathogenic G2019S LRRK2 variant, it 
seems fairly clear that LRRK2 kinase inhibitors can effectively reduce the resulting 
neurodegeneration in both mice (Lee et al., 2010) and rats (Daher et al., 2015; Nguyen et al., 2020). 
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These data are supported by observations  of an equivalent effect of introducing an artificial kinase 
inactivating mutation into the overexpressed LRRK2 protein (Lee et al., 2010; Tsika et al., 2015; 
Nguyen et al., 2020). Of note, mutations that perturb LRRK2 GTPase function, either by blocking 
binding to GTP or elevating the rate of GTP hydrolysis, cause a similar reduction in 
neurodegeneration, thus supporting the use of LRRK2 GTPase inhibitors as an alternative strategy 
(Nguyen et al., 2020).  
The above studies clearly demonstrate that LRRK2 kinase inhibition can be neuroprotective in vivo. 
However, there remains a question as to how accurately the neurodegeneration caused by viral 
over-expression of a pathogenic LRRK2 variant represents the normal dopaminergic cell death in PD, 
where LRRK2 is not over-expressed. So, what about other models of neurodegeneration? An 
alternative experimental system is viral transduction of α-synuclein. Unfortunately, results using 
these technologies are mixed. In the first study, Daher and colleagues found that PF-06447475 
reduced α-synuclein-induced neurodegeneration in rats (Daher et al., 2015). By contrast, Andersen 
and colleagues were unable to show neuroprotection or rescue of motor symptoms using PFE-360, 
although they did report a reversal of an aberrant subthalamic firing pattern that the authors 
describe as resembling alterations seen in PD (Andersen et al., 2018). However, in a follow-up report 
describing the effects of longer-term PFE-360 treatment, the same group found no improvement in 
subthalamic nucleus firing, although a mild improvement in motor function was observed (Andersen 
et al., 2019). Taking their observations together, the authors conclude that their findings “do not 
strongly support LRRK2 inhibition for the treatment of PD” (Andersen et al., 2019). 
There are many potential reasons for the disagreement, such as the different viral systems used, the 
degree of α-synuclein expression achieved and the treatment times used. Although structurally very 
similar (Figure 2), the LRRK2 inhibitors used could also be a factor. It is also worth observing that 
even if the results were in complete agreement, they would still need to be treated with caution, 
since the rate at which α-synuclein accumulates in the brains of PD patients cannot be anything like 
as fast as that achieved by viral transduction.  
With this in mind, recent observations made using the pesticide rotenone to induce dopaminergic 
neurodegeneration in mice may be insightful (Rocha et al., 2020). This study measured both 
rotenone-induced dopaminergic cell death and the preceding changes to endolysosomal and 
autophagic systems that mirror defects seen in the surviving neurons from patients with idiopathic 
PD (Rocha et al., 2020). Remarkably, the type I LRRK2 kinase inhibitor PFE-360 reduced the effects of 
rotenone on all these measures. It must be stressed that these data are only directly transferable to 
humans who develop PD following acute rotenone exposure, but these results are nonetheless 
encouraging. Chronic exposure to pesticides including rotenone are an established environmental 
cause of increased PD risk, and the endolysosomal and autophagic defects that were rescued are 
consistent with idiopathic PD. As such, these data point to LRRK2 inhibitors having use in idiopathic 
PD and LRRK2 PD. 
Despite the widespread use of the neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) to induce dopaminergic damage in rodent PD models 
(Schober, 2004), we are aware of only one report of an attempt to rescue the phenotype of animals 
treated with these compounds using LRRK2 inhibition. This study used a low dose of MPTP that was 
not toxic in wildtype animals, but induced significant impairments in transgenic mice that over-
express either wild-type LRRK2 or G2019S-LRRK2, with a greater effect seen in the G2019S animals 
(Arbez et al., 2020). Remarkably, treatment with LRRK2-IN-1 dramatically reduced dopaminergic cell 
death and also rescued motor deficits to a similar extent to L-DOPA (Arbez et al., 2020). There are 
clearly some caveats with these data, not least the choice of LRRK2 inhibitor – more selective 
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compounds are available – but these data are nonetheless encouraging. Perhaps most informative is 
the fact that an ordinarily sub-toxic dose of MPTP was used, which would have caused less 
dopaminergic damage than standard doses. Perhaps consistent with this, the rotenone study 
mentioned above used a dosing regimen optimised to cause the least amount of neurodegeneration 
required to guarantee a reproducible motor deficit (Cannon et al., 2009). As such, the studies of 
Rocha et al. and Arbez et al. most likely point to a situation where LRRK2 inhibitors may have great 
potential to prevent maintain motor function in PD patients, but only if administered while there are 
sufficient dopaminergic neurons remaining.  
Research into the therapeutic potential of LRRK2 ASOs in pre-clinical models is also thin on the 
ground, although the use of LRRK2 ASOs is to some extent informed by the pre-clinical work using 
LRRK2 inhibitors described above (and vice versa). The first study using LRRK2 ASOs is that of Zhao 
and colleagues, who investigated the effect of intracerebral ventricular injection of Lrrk2 ASOs on 
mice injected with synthetic α-synuclein fibrils (Zhao et al., 2017). Somewhat surprisingly, given that 
the two different ASOs used only achieved a ~50% reduction in Lrrk2 expression, both 
oligonucleotides markedly reduced α-synuclein aggregation and dopaminergic cell death, and almost 
entirely rescued motor defects (Zhao et al., 2017). In the absence of independent replication these 
observations must be treated with caution, but the idea that a modest knockdown of LRRK2 
expression is sufficient to elicit a significant biological effect in the mouse brain is supported by the 
only other paper using ASOs targeting LRRK2 in animal models. In this this report (Korecka et al., 
2020), Korecka and colleagues used an ASO that they have previously shown to perturb the normal 
splicing of human LRRK2 mRNA by causing exon 41 to be skipped causing no functional LRRK2 
protein produced (Korecka et al., 2019). When injected into the cerebral ventricles of transgenic 
mice expressing human wildtype or G2019S LRRK2, this ASO elicited significant decreases in 
phosphorylation of the LRRK2 substrate Rab10 and also affected autophagic flux, despite causing 
exon 41 to be skipped in no more than 30% of transcripts (Korecka et al., 2020). 
Taken together, these studies provide evidence that both strategies may prevent neurodegeneration 
and thus delay or halt the progression of PD. Furthermore, since modest effects on LRRK2 expression 
appear sufficient to elicit promising biological effects, the data suggest that LRRK2 ASOs may be the 
more effective strategy. In principle, this may suggest the existence of additional pathological 
mechanisms that are independent of LRRK2 kinase activity. However, the lack of publications and 
issues with reproducibility make these predictions extremely speculative. Perhaps more convincing 
is the suggestion that the degree of neurodegeneration present at time of treatment will be a 
decisive factor in determining whether inhibiting or knocking down LRRK2 can be effective. Where 
sufficient dopaminergic neurons remain, these strategies may maintain motor function; but if the 
disease is too far advanced, targeting LRRK2 may be to no avail. 
Final points of discussion 
There are clearly a wide range of therapeutic strategies aiming to treat both LRRK2 and idiopathic PD 
by reducing the function of this enigmatic protein. These include both ATP-competitive and non-ATP 
competitive kinase inhibitors, pharmacological inhibitors of LRRK2 GTPase activity, and knockdown 
of LRRK2 mRNA. The kinase inhibitor DNL151 and the antisense RNA molecule BIIB094 are currently 
in clinical trials with further results eagerly awaited. There is therefore optimism within the field, as 
well as a plethora of fall-back options should DNL151 and BIIB094 fail. 
Nonetheless, there are other aspects of LRRK2 biology that may in future become viable therapeutic 
targets. As mentioned, LRRK2 dimers are believed to have greater kinase activity that LRRK2 
monomers, and the cycling of LRRK2 between these states is has been suggested to play a key role in 
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the normal regulation of this protein (Berwick et al., 2019). Indeed, work performed in zebrafish 
models indicates the deletion of the C-terminal WD40 domain is sufficient to prevent dimerization, 
thereby reducing autophosphorylation and reducing the neurotoxicity of LRRK2 (Jorgensen et al., 
2009). Thus, disruption of LRRK2 dimerization can be expected to, in turn, impair LRRK2 kinase 
activity, creating a mechanism that could be harnessed for the development of selective inhibitors of 
LRRK2 kinase. Such approaches have already been used successfully to identify compounds that 
prevent dimerization of other proteins, for example ST2825, a heptapeptide that blocks dimerization 
of MyD88 (Loiarro et al., 2007). However, this may be a trickier task for LRRK2, since LRRK2 
dimerization appears to have several intramolecular interactions involved, with the WD40 and COR 
domains implicated in particular (Greggio et al., 2008, 2008; Jorgensen et al., 2009; Guaitoli et al., 
2016). As such, efficient disruption of LRRK2 dimers may require a cocktail of molecules, each 
targeting a different protein interaction interface. 
On a similar note, in addition to roles as a kinase and GTPase, LRRK2 has long been suggested to 
have a function as a scaffold protein, interacting with numerous other proteins to form dynamic 
signalling complexes at specific cellular localisations (Lewis and Manzoni, 2012; Berwick et al., 2019). 
As such, disruption of protein-protein interactions required for the pathogenic effects of LRRK2 may 
be fertile ground for drug discovery. Nonetheless, whilst many hundreds of LRRK2 interaction 
partners have been reported, when the expression levels of these proteins have been modulated in 
cellular models, very few appear to exert a robust influence on measures relevant to pathogenicity 
of PD-causing LRRK2 variants. An important exception, however, may be 14-3-3 proteins. 14-3-3 
proteins a bind LRRK2 in a manner dependent on the phosphorylation of LRRK2. Phosphorylation 
sites to which 14-3-3 proteins associate include Ser910, Ser935, in the LRR domain (Nichols et al., 
2010), Ser1444 in the Roc domain (Muda et al., 2014) and Thr2524 at the very C-terminus 
(Manschwetus et al., 2020). Whilst the interplay between these 14-3-3 binding events is complex 
and not yet fully understood, the functional consequences of LRRK2 interacting with these proteins 
are clear. Most notably, binding of 14-3-3 proteins to LRR domain residues stabilises LRRK2 in a 
monomeric and cytoplasmic form that can be assumed to have decreased kinase activity (depicted in 
Figure 3). Consistently, pathogenic LRRK2 mutations have been reported to disrupt LRRK2-14-3-3 
interactions (Nichols et al., 2010; Lavalley et al., 2016). Based on these and other observations, 
Soliman and colleagues have speculated that small molecule stabilisers of 14-3-3 protein-protein-
interactions, some of which have recently been described in the literature (Ballone et al., 2018), 
could be used to produce molecules that stabilize LRRK2-14-3-3 complexes (Soliman et al., 2020). 
We await the next instalment of this story. 
Finally, it is important to mention the impact two very recent breakthroughs in LRRK2 structural 
biology that have already provided data relevant to LRRK2 inhibitor development. In the first work, 
Watanabe and colleagues used a combination of cryo-electron tomography and integrative 
modelling to produce a 14Å resolution in situ model for the entire LRRK2 protein bound to 
microtubules (PDB:6XR4) (Watanabe et al., 2020). This model recapitulated the filamentous LRRK2 
phenotype observed by others, where LRRK2 filament formation is enhanced by both most LRRK2 
pathogenic mutants and conventional LRRK2 kinase inhibitors (Blanca Ramirez et al., 2017; Schmidt 
et al., 2019), and found that LRRK2 filaments form via homotypic interactions between COR and 
WD40 domains (Watanabe et al., 2020). Fascinatingly, Deniston and colleagues integrated the 6XR4 
structure with their own high resolution (3.5Å) cryo-electron microscopy structure of amino acids 
1327-2527 of LRRK2, containing Roc, COR, kinase and WD40 domains, to reveal further insights 
(Deniston et al., 2020). Most notably, this group confirmed the prediction made by Watanabe et al 
that LRRK2 would be more likely to form filaments when in a closed kinase confirmation, which 
provides a rationale for why conventional LRRK2 kinase inhibitors (i.e. ATP-competitive or Type I), 
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which lock LRRK2 in a closed kinase confirmation, promote filament formation. In support of this, 
the Type II kinase inhibitors Ponatinib (O’Hare et al., 2009) and GZD-824 (Ren et al., 2013), which 
would be expected to lock LRRK2 in an open kinase confirmation, were found prevent filament 
formation (Deniston et al., 2020). Interestingly, this latter observation mirrors those made for the 
LRRK2 GTPase inhibitors, compounds 68 and 60 (Blanca Ramirez et al., 2017). 
In conclusion, therefore, with so many routes to achieving LRRK2 inhibition being taken, the 
prospects for developing new PD medications based around targeting LRRK2 are good. Where lead 
molecules and different strategies fall by the wayside, there are plenty of alternatives to take over. 
Nonetheless, with two molecules in clinical trials, the extent to which these treatments bring clinical 
benefits will undoubtedly be the hot topic over the next few years.  
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to 
PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2019/20 (Alexander et al., 2019). 
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Table 1: Overview of the current treatments for Parkinson’s disease. 
This table summarises the most commonly used PD treatments that target motor dysfunction by re-
establishing the physiological dopamine pathway. However, some non-motor symptoms also 
respond to the treatments (Jankovic, 2008; Chaudhuri and Schapira, 2009; Duty and Jenner, 2011; 
AlDakheel et al., 2014; Postuma et al., 2015; Pfeiffer, 2016; Armstrong and Okun, 2020). 
 
Target   Strategy  Treatment  
Motor symptoms  
(loss of dopaminergic 
neurons and striatal  
dopamine depletion)  
Dopamine  
Replacement  
Dopamine precursor (e.g., L-DOPA), dopamine 
agonists (e.g., ropinirole)  
Inhibition of  
dopamine degradation  
Monoamine oxidase-B inhibitors (e.g., rasagiline), 
catecholamine-O-methyltransferase inhibitors 
(e.g., entacapone)   
Glutamatergic activity 
decrease (promote dopamine 
synthesis) and other 
neurotransmitters  
Amantadine, NMDA Receptors antagonist, 
cholinesterase inhibitors  
Surgical Intervention  e.g., Deep Brain Stimulation   
Non-pharmacological 
approaches  
Exercise, rehabilitative therapy, physiotherapy  
Non-motor symptoms  
Approaches used in the 
general population  
Psychiatric symptoms (e.g., depression, anxiety, 
psychosis): dopamine-related (Quetiapine), 
antidepressants, serotonin and norepinephrine 
reuptake inhibitors, cholinesterase inhibitors  
Cognitive impairments: cholinesterase inhibitors, 













Figure 1: LRRK2 structure and mutations  
LRRK2 is a homodimer belonging to the ROCO family of GTPases. LRRK2 contains multiple domains: 
protein-protein interaction domains ARM (armadillo), ANK (Ankyrin-like), LRR (leucine rich repeat) 
and WD40 (all in pink); a serine-threonine kinase domain (in orange); and a Roc (Ras of complex 
proteins)-COR (C-terminal of Roc) tandem domain conferring GTPase activity (in blue). The arrows 
indicate the putative intramolecular interactions. The locations of the pathogenic mutations are 






This article is protected by copyright. All rights reserved. 
 
Figure 2: Chemical structures of the LRRK2 inhibitors described in this review 
The chemical structures of the selective LRRK2 inhibitors mentioned by name in this article are 
shown. Structures were generated using ACD/ChemSketch (ACD Labs) with structures cleaned and 
most likely tautomeric forms selected. 
 
 






Figure 3: Sites of action of the LRRK2 inhibitors described in this review 
The various types of therapeutic strategy that are under-development or have been proposed for 
targeting LRRK2 are summarized in the figure. Proposed strategies are written in italics. For 
simplicity, non-selective kinase inhibitors (e.g. staurosporine, ponatinib) are omitted. ATP-
competitive kinase inhibitors are listed by chemical class; note that the categorization of DNL-151 
and DNL-201 are presumed based on patents held by the manufacturer. 
 
